[혁신형 제약기업 점검]④ JW중외제약, 재인증 변수 윤리심사

JW Pharma's bid to reclaim biotech certification reveals the critical tension between R&D innovation and regulatory credibility. The company demonstrates strong operational fundamentals—10%+ R&D investment and Epaminurad in phase 3 trials—yet faces a decisive barrier: unresolved compliance violations and legal penalties that directly conflict with certification criteria emphasizing corporate integrity. Regulatory outcomes will signal whether established pharma companies can overcome historical ethics deficits through demonstrated innovation and financial performance.